Head to Head Survey: Ocugen (OCGN) and Its Rivals

Ocugen (NASDAQ: OCGN) is one of 29 publicly-traded companies in the “Surgical appliances & supplies” industry, but how does it weigh in compared to its rivals? We will compare Ocugen to related companies based on the strength of its dividends, institutional ownership, profitability, earnings, analyst recommendations, risk and valuation.

Volatility & Risk

Ocugen has a beta of 3, suggesting that its share price is 200% more volatile than the S&P 500. Comparatively, Ocugen’s rivals have a beta of 1.13, suggesting that their average share price is 13% more volatile than the S&P 500.

Valuation and Earnings

This table compares Ocugen and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Ocugen N/A -$8.64 million -0.04
Ocugen Competitors $1.39 billion $142.47 million 17.54

Ocugen’s rivals have higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Ocugen and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ocugen N/A -34.96% 18.40%
Ocugen Competitors -125.72% -66.50% -24.96%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Ocugen and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocugen 0 0 0 0 N/A
Ocugen Competitors 284 1009 1715 86 2.52

As a group, “Surgical appliances & supplies” companies have a potential upside of 10.30%. Given Ocugen’s rivals higher possible upside, analysts clearly believe Ocugen has less favorable growth aspects than its rivals.

Institutional & Insider Ownership

56.3% of shares of all “Surgical appliances & supplies” companies are held by institutional investors. 19.7% of Ocugen shares are held by insiders. Comparatively, 8.2% of shares of all “Surgical appliances & supplies” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Ocugen Company Profile

Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company based in Malvern, Pennsylvania.

Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.